공고 • Sep 23
Therma Bright Inc., Annual General Meeting, Nov 25, 2025 Therma Bright Inc., Annual General Meeting, Nov 25, 2025. Location: ontario, toronto Canada 공고 • Sep 27
Therma Bright Inc. announced that it expects to receive CAD 3 million in funding Therma Bright Inc. announced a non-brokered private placement that it will issue up to 50,000,000 common shares of the company at an issue price of CAD 0.06 per share for the gross proceeds of up to CAD 3,000,000 on September 27, 2024. All securities issued in connection with the Concurrent Private Placement will be subject to a statutory hold period of four months and one day following the date of issuance in accordance with applicable Canadian securities laws. The closing of the Concurrent Private Placement may take place in one or more tranches as determined by the Company and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals, including the conditional approval from the TSXV. The Company may pay finders' fees to eligible finders in connection with the Concurrent Private Placement, subject to compliance with applicable securities laws and the policies of the TSXV. 공고 • Sep 18
Therma Bright Inc. announced that it expects to receive CAD 0.4045 million in funding Therma Bright Inc. announced a private placement that it will issue 5,056,250 common shares at a deemed price of CAD 0.08 per share for the gross proceeds of CAD 404,500 on September 18, 2024. The transaction will include participation from AI4LYF for CAD 280,000 making up the bulk of the shares. All securities issued under the debt settlements will be subject to a hold period expiring four months and
one day from their date of issuance. 공고 • Sep 12
Therma Bright Inc. Appoints Douglas S. Sommerville to Its Advisory Board Therma Bright Inc. announced the addition of Douglas S. Sommerville to its Advisory Board. With 30 years of experience in sales and operations within the medical device industry, Mr. Sommerville brings a wealth of expertise to the Company. Mr. Sommerville previously served as the Head of Country for Teva Canada Limited, where he oversaw the Canadian operations of Teva's generic drug business. Prior to this role, he was the Global Vice President of Infusion Systems at Baxter Healthcare International. In this position, he managed global sales, marketing, and distribution for Baxter's infusion pumping devices, intravenous administration sets, and pain management and ambulatory infusion devices. Furthermore, Mr. Sommerville served as Chairman of the Canadian Generic Pharmaceutical Association until his retirement from Teva in 2018 and is a U.S. patent holder (number 5,304,163) for the "Integral Reconstitution Device," which is marketed worldwide by Baxter Healthcare under the trade name Mini Bag PLUS. Mr. Sommerville will join Mr. Raimondo, who joined the Advisory Board last month, and will leverage his network to introduce Therma Bright and its innovative diagnostic and medical device technologies. 공고 • Jun 21
Therma Bright Inc. announced that it has received CAD 1 million in funding On June 21, 2024, Therma Bright Inc., closed the transaction. The company issued 14,550,000 units at a price of CAD 0.01 per unit for the gross proceeds of CAD 145,500 in its second and final tranche closing. All securities issued under the Final Tranche are subject to a hold period expiring October 21, 2024, in accordance with applicable securities laws and the policies of the TSXV. A director and officer of the company participated in the final tranche and purchased 1,100,000 units for CAD 11,000. 공고 • May 23
Therma Bright Inc. announced that it expects to receive CAD 1 million in funding Therma Bright Inc. announced a non-brokered private placement of up to 100,000,000 units at price CAD 0.01 per unit for gross proceeds CAD 1,000,000 on May 22, 2024. Each unit will be comprised of one common share in the capital of the Company and one-half non-transferable common share purchase warrant. Each full warrant will entitle the holder to purchase over three years one additional share at an exercise price of CAD 0.05 during the first year and CAD 0.10 during the second and third years. The transaction is subject to accordance with the policies of the TSX Venture Exchange. The Offering is expected to close on or before June 7, 2024. All securities issued and sold under the Offering will be subject to a hold period expiring four months and one day from their date of issuance. Completion of the Offering and the payment of any finders' fees remain subject to the receipt of all necessary regulatory approvals, including the approval of the TSXV. 공고 • Oct 19
Therma Bright Inc., Annual General Meeting, Dec 18, 2023 Therma Bright Inc., Annual General Meeting, Dec 18, 2023. 공고 • Jun 09
Therma Bright Inc. and Inretio Inc. Announces Successful Completion of Good Laboratory Practice Study for Its Breakthrough Preva™? Mechanical Thrombectomy Device Therma Bright Inc. and its investment Inretio Inc. has announced the successful completion of a Good Laboratory Practice (GLP) study for its breakthrough PREVA™? mechanical thrombectomy device. This significant milestone brings the device one step closer to human clinical trials and eventual market availability, marking a major advancement in the treatment of ischemic stroke. The GLP study, conducted at the Shamir Medical Center's Research Unit, demonstrated the PREVA™? device's ability to effectively remove blood clots, confirming its potential to revolutionize the treatment of ischemic strokes. GLP studies are essential for this class of medical device and usually precede the initiation of First-in-Human (FIH) studies that are requested by the various regulatory agencies, including Israel's Ministry of Health, U.S. Food and Drug Administration (U.S. FDA), Health Canada (HC), European Medicines Agency (EMA) and Pharmaceuticals and Medical Devices Agency (PMDA-Japan). Current thrombectomy procedures are based on stents that open inside the clot without aspiration, leading to potential fragmentation and secondary damage to the brain tissue. This can result in new blockages downstream, causing significant impact on the patient's quality of life. The PREVA™? device is uniquely designed to mechanically remove blood clots from the brain, using a distal basket to 'ensnare' the clot, protecting the brain from any sub-clots breaking off during the procedure. This leads to more successful revascularization of the brain, preventing further damage and complications, and potentially improving patient outcomes. Inretio anticipates starting clinical trials for the PREVA™? device in approximately four months. The results from these studies will be submitted to the Israeli Ministry of Health for Clinical Trial clearance in humans, marking a significant milestone towards the device's commercialization. In other news, Health Canada has requested a long-term stability study of the AcuVidTM Covid-19 Rapid Antigen Saliva Test to determine shelf life, as well as a comprehensive post-production validation study by a third (3rd) party independent lab to further ensure that the test's sensitivity remains intact. Both studies are complex and will require manufacturing of additional test lots and the identification and hiring of a reputable third (3rd) party, highly specialized lab partner to conduct these studies. 
